Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist.
A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results.
Palliative Care in Patients with Advanced NSCLC Varies Among Racial/Ethnic Groups and Insurance Providers
Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer.
Promising Results for Patients with Advanced NSCLC Treated with Flat-Dose Nivolumab plus Weight-Based Ipilimumab
Evaluation of flat-dose nivolumab plus weight-based ipilimumab in patients with advanced non–small-cell lung cancer and poorer prognosis demonstrates efficacy with a tolerable safety profile.
A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.
A recent study from the United Kingdom in younger adults with non–small-cell lung cancer found poor survival outcomes in patients without targetable mutations.
Based on positive results of the KRYSTAL-1 clinical trial, adagrasib was granted accelerated FDA approval for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.
A recent study assessing the prognostic value of circulating tumor cells in patients with lung cancer found an association with poorer patient outcomes, with more pronounced effect on small-cell lung cancer.
Promising Response with Sotorasib in a Patient with KRAS G12C–Mutated Lung Cancer and Brain Metastases
Sotorasib in a patient with KRAS G12C–mutated lung cancer and brain metastases resolved or shrank brain lesions and improved mental status.
In patients with non–small-cell lung cancer, broad and rapid genomic profiling are recommended for use at all stages of clinical management to improve patient outcomes.
Study determines that permanently discontinuing immune checkpoint inhibitors after grade ≥2 immune-related adverse events is an appropriate response for patients with stage IV non–small-cell lung cancer.
A review of multiple clinical trials in patients with non–small-cell lung cancer and brain metastases finds adagrasib effectively penetrates the central nervous system, resulting in good response rates.
Web Exclusives | December 5, 2022
A guide to the departments and people you should be working with to collect the data pertinent to your navigation program.
Web Exclusives | December 5, 2022
Navigators in the Metric Pilot Study increased the number of palliative care referrals through the use of a symptom assessment tool and worked together to improve the assessment process.
Despite advantages for molecular testing for non–small-cell lung cancer, the testing rate remains low, with white patients and female patients having a higher likelihood of undergoing molecular testing.
Maintaining quality of life and independence was found to be a high priority for patients with non–small-cell lung cancer and should be regularly assessed by the care team.
All patient ethnic/racial groups demonstrated improved clinical outcome when experiencing immune-related adverse events while receiving therapy with an immune checkpoint inhibitor, but Hispanic patients appear to derive less benefit.
In a recent study, circulating tumor cells were found to act as a precise biomarker in early assessment and therapy monitoring in patients with lung cancer.
In a recent trial of patients with advanced non–small-cell lung cancer, liquid biopsy led to faster molecular results and shortened time to treatment.
CodeBreak 200 phase 3 trial results demonstrated that sotorasib achieved a more robust survival benefit versus docetaxel in patients with advanced non–small-cell lung cancer harboring KRAS G12C mutation.
Biomarker testing is the standard of care in advanced non–small-cell lung cancer, but the rate of patients receiving test results prior to initiating treatment is low.
Study finds that frequencies of mutations commonly found in patients with non–small-cell lung cancer vary among members of 3 racial groups.
Patients with Lung Cancer Harboring KRAS G12C Mutation and Higher PD-L1 Expression Benefit from Immunotherapy
Study of patients with lung adenocarcinoma found that patients with KRAS G12C mutation and high PD-L1 expression benefit more from immunotherapy compared with patients with other KRAS mutations.
Adagrasib Demonstrates CNS Penetration and Intracranial Activity in Patients with KRAS G12C-Mutated NSCLC with Brain Metastases
A study in patients with KRAS G12C-mutated non–small-cell lung cancer with brain metastases found adagrasib to demonstrate intracranial activity while being well tolerated.
Study finds circulating tumor DNA reveals disease recurrence before radiographic evidence in patients with non–small-cell lung cancer.
Recent study showed that KRAS mutation in patients with non–small-cell lung cancer predicted superior response to first-line immunotherapy.
Real-world analysis of mutations in non–small-cell lung cancer showed similar frequencies of common KRAS and EGFR variants in Black and White Americans, but higher EGFR G719S variant was seen in Black Americans.
When clinicians and patients rely on different terminology for the term “cure” in cancer treatment, it can lead to patient dissatisfaction and confusion.
Next-generation sequencing at initial workup of the patient with advanced non–small-cell lung cancer can shorten time between diagnosis and treatment and may improve survival.
Recent study found that the use of sotorasib after anti–PD-L1 therapy in patients with NSCLC increased the chance of severe adverse events and liver toxicity.